Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib combinations in trastuzumab-resistant HER2-positive metastatic breast cancer
2012-000598-22Phase 2Terminated
- Sponsor
- BNGO
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Tyverb + trastuzumab with Tyverb + capecitabine (2 arms). Primary endpoint: 6-month progression-free survival rate. Started Feb 2013; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000598-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000598-22.